PL401282A1 - The use of inhibitors of cysteine proteases as a factor inhibiting growth of tumor cells - Google Patents
The use of inhibitors of cysteine proteases as a factor inhibiting growth of tumor cellsInfo
- Publication number
- PL401282A1 PL401282A1 PL401282A PL40128212A PL401282A1 PL 401282 A1 PL401282 A1 PL 401282A1 PL 401282 A PL401282 A PL 401282A PL 40128212 A PL40128212 A PL 40128212A PL 401282 A1 PL401282 A1 PL 401282A1
- Authority
- PL
- Poland
- Prior art keywords
- cysteine
- inhibitors
- proteases
- tumor cells
- inhibiting growth
- Prior art date
Links
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
- 235000018417 cysteine Nutrition 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 230000004614 tumor growth Effects 0.000 title 1
- 101000722964 Gallus gallus Cystatin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Przedmiotem wynalazku jest zastosowanie inhibitorów proteaz cysteinowych w postaci liofilizatu monomeru ovocystatyny, jako substancji czynnej srodka farmaceutycznego hamujacego wzrost komórek nowotworowych pochodzenia nablonkowego oraz komórek czerniaka, do stosowania terapeutycznego w leczeniu chorób nowotworowych.The subject of the invention is the use of cysteine protease inhibitors in the form of ovocystatin monomer lyophilisate, as an active ingredient of a pharmaceutical agent that inhibits the growth of cancer cells of epithelial origin and melanoma cells, for therapeutic use in the treatment of cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401282A PL401282A1 (en) | 2012-10-19 | 2012-10-19 | The use of inhibitors of cysteine proteases as a factor inhibiting growth of tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401282A PL401282A1 (en) | 2012-10-19 | 2012-10-19 | The use of inhibitors of cysteine proteases as a factor inhibiting growth of tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL401282A1 true PL401282A1 (en) | 2013-06-10 |
Family
ID=48539638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401282A PL401282A1 (en) | 2012-10-19 | 2012-10-19 | The use of inhibitors of cysteine proteases as a factor inhibiting growth of tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL401282A1 (en) |
-
2012
- 2012-10-19 PL PL401282A patent/PL401282A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220008A1 (en) | Parp1 inhibitors | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| EA202092456A2 (en) | COMBINATION THERAPY INCLUDING MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR TREATMENT OF VARIOUS TYPES OF CANCER | |
| MX375752B (en) | BRUTON'S TYROSINE KINASE INHIBITORS. | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| EA201591752A1 (en) | DIPEPTIDE AND TRIPEPTID EPOXYETONIC PROTEASE INHIBITORS | |
| BR112015011756A2 (en) | glutamase inhibitors and methods of use | |
| EA201590855A1 (en) | COMPOUNDS OF PYRROPOLYMIDININE AS KINAZ INHIBITORS | |
| MX2015017964A (en) | Bromodomain inhibitors. | |
| JO3366B1 (en) | Pyrazolyl quinoxaline kinase inhibitors | |
| DOP2015000304A (en) | BROMODOMINIUM CRYSTAL INHIBITORS | |
| MX2015006939A (en) | Treatment of cancer with heterocyclic inhibitors of glutaminase. | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| EA201791516A1 (en) | METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS | |
| EA201591751A1 (en) | TRIPEPTIDE EPOKEKETONE PROTEASE INHIBITORS | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| EA201691155A1 (en) | COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES | |
| EA201692480A1 (en) | PHARMACEUTICAL COMPOSITION | |
| CL2015002897A1 (en) | Bace1 inhibitors | |
| EA201690039A1 (en) | RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION | |
| EP3513789A3 (en) | Prophylactic and therapeutic agents for fgfr3 diseases | |
| MX2016002580A (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases. | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer |